Testing how chemotherapy affects kids’ urinary markers
Part of Cancer, Kidney & urinary clinical trials.
This study looks at urinary (bladder and urine) measurements in children who previously had cancer and were treated with certain chemotherapy drugs. It may help researchers understand how past chemotherapy can affect bladder function and related health markers over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 5 and 13 years old
- Have had a cancer diagnosis in the past
- Have received chemotherapy that included VCR (vincristine) and/or DOX (doxorubicin)
- Have finished chemotherapy at least 1 year before joining and completing surveys
- Do not have a primary tumor in the pelvis
- Do not have had pelvic radiation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether showing parents and caregivers an educational video improves how well children follow their treatment plan for voiding dysfunction (problems with urination). It may help your child stick to their therapy and see better results.
This study compares a new combination of chemotherapy drugs delivered directly into the bladder versus standard treatment for people with non-muscle invasive bladder cancer that has returned or not responded to prior therapy. It aims to see if the new treatment helps prevent the cancer from coming back.
This study looks at how well different treatments work for older adults with bladder cancer that has spread and who cannot take cisplatin. It also checks if geriatric assessments help guide care.
This trial checks if a DNA blood test can help decide who needs extra chemo after bladder or upper urinary tract cancer surgery. It tests whether watching for cancer DNA in the blood can match patients to the right treatment.
This study tests a new way to measure bladder pressure in children to better understand bladder problems. It may help doctors tailor treatments for conditions like leaky bladder or trouble emptying.
This trial tests a new targeted drug, BL-M07D1, against standard chemotherapy in people with advanced bladder cancer that has grown after immunotherapy. It may offer a new treatment option for those with a specific protein (HER2) on their cancer cells.
Hear when a new Bladder Dysfunction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.